Micropapillary Thyroid Carcinoma: Not So Harmless as it Seems. A 5-Year Follow-Up Cohort Retrospective Study
DOI:
https://doi.org/10.14738/bjhmr.101.14049Keywords:
thyroid neoplasms, thryroidectomy, surgical oncologyAbstract
Introduction: Differentiated thyroid cancer is becoming increasingly prevalent mostly due to the increasing incidence of micropapillary carcinoma. For low-risk tumors, hemithyroidectomy does not reduce survival and may be associated with higher local recurrence. This study aimed to compare Micropapillary versus Papillary thyroid carcinomas regarding overall survival and disease-free survival. Methods: A retrospective, unicentric, cohort study was carried between 2012 and 2016. Consecutive cases with (micro)papillary thyroid carcinoma were enrolled and divided in microcarcinoma group and control group. Exclusion criteria were loss to follow-up, previous thyroid surgery and non-operative treatment. A comparison of several clinical and pathological parameters, recurrence rate and cumulative survival was performed between groups. Results: Patients with micropapillary carcinomas were younger and frequently asymptomatic. 6.5% of these carcinomas presented a benign cytology (Bethesda II) in this study. 18.9% of these patients were submitted to hemithyroidectomy but 71.4% were thereafter totalized. Micropapillary carcinomas presented higher rate of multifocality but similar lymph node invasion rate, lymph node dissection rate and adjuvant iodine therapy. Patients with micropapillary carcinomas presented less advanced staging but similar recurrence rate and time to recurrence; moreover, higher stage was only related with (older) age of presentation. Conclusions: In this study micropapillary carcinomas presented better staging but similar recurrence rate comparing with papillary carcinomas. Moreover, most of these patients were submitted to totalization. These results question if hemithyroidectomy is still a good option for micropapillary carcinomas and if this staging system is adequate. Larger studies with longer follow-up are needed to confirm or refute these results.
References
Schuster-Bruce J, Jani C, Goodall R, Kim D, Hughes W, Salciccioli JD, et al. A Comparison of the Burden of Thyroid Cancer Among the European Union 15+ Countries, 1990-2019: Estimates From the Global Burden of Disease Study. JAMA Otolaryngology–Head & Neck Surgery. 2022.
Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of oncology : official journal of the European Society for Medical Oncology. 2019;30(12):1856-83.
Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009;115(16):3801-7.
Xu S, Han Y. The Overdiagnosis of Thyroid Micropapillary Carcinoma: The Rising Incidence, Inert Biological Behavior, and Countermeasures. Journal of oncology. 2021;2021:5544232.
Lin JD. Increased incidence of papillary thyroid microcarcinoma with decreased tumor size of thyroid cancer. Medical oncology (Northwood, London, England). 2010;27(2):510-8.
Jeon MJ, Kim WG, Chung KW, Baek JH, Kim WB, Shong YK. Active Surveillance of Papillary Thyroid Microcarcinoma: Where Do We Stand? European Thyroid Journal. 2019;8(6):298-306.
Kartal K, Aygün N, Uludağ M. Clinicopathologic Differences Between Micropapillary and Papillary Thyroid Carcinoma. Sisli Etfal Hastanesi tip bulteni. 2019;53(2):120-4.
Liu FF, Shen DH, Zhao HM, Ma YT, Yang XD, Zhao XY. [Significance of micropapillary histopathological subtype of thyroid carcinoma]. Zhonghua bing li xue za zhi = Chinese journal of pathology. 2020;49(5):454-7.
Pitt SC, Sippel RS, Chen H. Contralateral papillary thyroid cancer: does size matter? American journal of surgery. 2009;197(3):342-7.
Cai J, Fang F, Chen J, Xiang D. Unilateral Multifocality and Bilaterality Could Be Two Different Multifocal Entities in Patients with Papillary Thyroid Microcarcinoma. BioMed Research International. 2020;2020:9854964.
Yang R, Zhang S, Huang T, Ming J, Yang P, Zhu J, et al. [Construction and verification of lymph node metastasis model of cN0 stage thyroid micropapillary carcinoma and discussion of surgical methods]. Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery. 2021;35(2):137-40.
Gao R, Jia X, Liang Y, Fan K, Wang X, Wang Y, et al. Papillary Thyroid Micro Carcinoma: The Incidence of High-Risk Features and Its Prognostic Implications. Front Endocrinol (Lausanne). 2019;10:74-.
ZHAO. JLB. Surgical safety analysis of retained glands for micro-papillary thyroid carcinoma. Clinical Medicine of China. 2018(12):149-52.
Ahn JH, Kwak JH, Yoon SG, Yi JW, Yu HW, Kwon H, et al. A prospective randomized controlled trial to assess the efficacy and safety of prophylactic central compartment lymph node dissection in papillary thyroid carcinoma. Surgery. 2022;171(1):182-9.
Choi SM, Kim JK, Lee CR, Lee J, Jeong JJ, Nam KH, et al. Completion Total Thyroidectomy Is Not Necessary for Papillary Thyroid Microcarcinoma with Occult Central Lymph Node Metastasis: A Long-Term Serial Follow-Up. Cancers. 2020;12(10).
Lee YD. Surgical Strategy for Papillary Thyroid Microcarcinoma. jkta. 2014;7(1):48-56.
Kwon H, Jeon MJ, Kim WG, Park S, Kim M, Song DE, et al. A comparison of lobectomy and total thyroidectomy in patients with papillary thyroid microcarcinoma: a retrospective individual risk factormatched cohort study. European journal of endocrinology. 2017;176(4):371-8.
Agha R, Abdall-Razak A, Crossley E, Dowlut N, Iosifidis C and Mathew G, for the STROCSS Group. The STROCSS 2019 Guideline: Strengthening the Reporting of Cohort Studies in Surgery. International Journal of Surgery 2019;72:156-165.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Urânia Fernandes, Gonçalo Guidi, Daniela Martins, Bruno Vieira, Clara Leal, Rita Marques, Carlos Santos, João Gaspar, João Pinto-de-Sousa
This work is licensed under a Creative Commons Attribution 4.0 International License.
